
    
      The purpose of this study is to determine the safety and maximum tolerated dose of birinapant
      (TL32711) as a 30 minute intravenous infusion once a week, for 2 consecutive weeks, when
      combined with standard regimens of chemotherapy in subjects with advanced or metastatic solid
      tumors. Additionally the study will assess anti-tumor activity, pharmacokinetics, and
      exploratory biomarkers as a measurement of pharmacodynamic effects.
    
  